B‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity?
dc.contributor.author | Kalra, Vaneet Kumar | en_US |
dc.contributor.author | Aggarwal, Sanjeev | en_US |
dc.contributor.author | Arora, Prem | en_US |
dc.contributor.author | Natarajan, Girija | en_US |
dc.date.accessioned | 2014-11-04T16:35:09Z | |
dc.date.available | WITHHELD_13_MONTHS | en_US |
dc.date.available | 2014-11-04T16:35:09Z | |
dc.date.issued | 2014-11 | en_US |
dc.identifier.citation | Kalra, Vaneet Kumar; Aggarwal, Sanjeev; Arora, Prem; Natarajan, Girija (2014). "B‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity?." Pediatric Pulmonology 49(11): 1106-1111. | en_US |
dc.identifier.issn | 8755-6863 | en_US |
dc.identifier.issn | 1099-0496 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/109265 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Chronic Lung Disease | en_US |
dc.subject.other | Preterm Neonates | en_US |
dc.subject.other | B‐Type Natriuretic Peptide | en_US |
dc.title | B‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity? | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/109265/1/ppul22942.pdf | |
dc.identifier.doi | 10.1002/ppul.22942 | en_US |
dc.identifier.source | Pediatric Pulmonology | en_US |
dc.identifier.citedreference | Cuna A, Kandasamy J, Fineberg N, Sims B. B‐type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol 2013; 3: 33 – 36. | en_US |
dc.identifier.citedreference | Vijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. B‐type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012; 160: 111 – 115, e111. | en_US |
dc.identifier.citedreference | Nuntnarumit P, Chongkongkiat P, Khositseth A. N‐terminal‐pro‐brain natriuretic peptide: a guide for early targeted indomethacin therapy for 1patent ductus arteriosus in preterm Infants. Acta Paediatr 100: 1217 – 1221. | en_US |
dc.identifier.citedreference | Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723 – 1729. | en_US |
dc.identifier.citedreference | Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214 – e224. | en_US |
dc.identifier.citedreference | Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529 – 534. | en_US |
dc.identifier.citedreference | Walsh M, Engle W, Laptook A, Kazzi SN, Buchter S, Rasmussen M, Yao Q. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved ? Pediatrics 2005; 116: 857 – 861. | en_US |
dc.identifier.citedreference | Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343 – 353. | en_US |
dc.identifier.citedreference | Cantinotti M, Storti S, Parri MS, Murzi M, Clerico A. Reference values for plasma B‐type natriuretic peptide in the first days of life. Clin Chem 2009; 55: 1438 – 1440. | en_US |
dc.identifier.citedreference | Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009; 48: 503 – 512. | en_US |
dc.identifier.citedreference | Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N‐terminal pro‐B‐type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27: 381 – 386. | en_US |
dc.identifier.citedreference | Akcan AB, Kardelen F, Oygucu SE, Kocabaş A, Ozel D, Akbaş H, Oygür N. The efficacy of cardiac findings in assessing the outcome in preterms with bronchopulmonary dysplasia. Indian J Pediatr 2013. DOI 10.1007/s12098‐013‐0994‐y | en_US |
dc.identifier.citedreference | Mannarino S, Garofoli F, Mongini E, et al. BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev 2010; 86: 295 – 298. | en_US |
dc.identifier.citedreference | Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994; 266: L308 – 315. | en_US |
dc.identifier.citedreference | Klinger JR, Warburton RR, Pietras L, Hill NS. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol 1998; 84: 1646 – 1652. | en_US |
dc.identifier.citedreference | Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865 – 870. | en_US |
dc.identifier.citedreference | Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, Nir A. Amino‐terminal pro‐brain‐type natriuretic peptide: heart or lung disease in pediatric respiratory distress ? Pediatrics 2005; 115: 1347 – 1350. | en_US |
dc.identifier.citedreference | Parekh N, Maisel AS. Utility of B‐natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 2009; 24: 155 – 160. | en_US |
dc.identifier.citedreference | Collaco JM, Romer LH, Stuart BD, et al. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol 2012; 47: 1042 – 1053. | en_US |
dc.identifier.citedreference | Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline‐membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357 – 368. | en_US |
dc.identifier.citedreference | Jobe AH. What is BPD in 2012 and what will BPD become ? Early Hum Dev 2012; 88: S27 – S28. | en_US |
dc.identifier.citedreference | Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res Dec 1999; 46: 641 – 643. | en_US |
dc.identifier.citedreference | Mourani PM, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004; 170: 1006 – 1013. | en_US |
dc.identifier.citedreference | Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120: 1260 – 1269. | en_US |
dc.identifier.citedreference | Yates AR, Welty SE, Gest AL, Cua CL. Myocardial tissue Doppler changes in patients with bronchopulmonary dysplasia. J Pediatr 2008; 152: 766 – 770, 770 e761. | en_US |
dc.identifier.citedreference | Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121: 317 – 325. | en_US |
dc.identifier.citedreference | Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321 – 328. | en_US |
dc.identifier.citedreference | Gotze JP, Kastrup J. Plasma pro‐brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest Suppl 2001; 234: 47 – 51. | en_US |
dc.identifier.citedreference | Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B‐type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol 2009; 54: 1467 – 1475. | en_US |
dc.identifier.citedreference | Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F. Point‐of‐care testing for B‐type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci Spring 2011; 41: 131 – 137. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.